NYSE:VAPO

Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX

Retrieved on: 
Thursday, December 14, 2023
Shareholder, NYSE, OTC Markets Group, OTCQX, Patient, VAPO, Cryptocurrency, Vapotherm

EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.

Key Points: 
  • EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately.
  • Vapotherm anticipates that its common stock will begin trading on the OTCQX Market ("OTCQX"), the highest market tier operated by OTC Markets Group, Inc. on December 15, 2023 under its current symbol VAPO.
  • Investors are expected to continue to be able to access accurate information, including stock price quotes, and execute trades.
  • Stockholders will not be required to exchange any shares, and the Company expects electronic trading to be available without any material disruption.

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

Retrieved on: 
Tuesday, November 28, 2023
Respiratory Care Week, VAPO, HVT, Hospital, NYSE, Patient, Vapotherm, Health, Education, Nursing

The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.

Key Points: 
  • The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October culminating in the American Association for Respiratory Care Congress 5-8 November.
  • Dr. Jessica Whittle, Chief Medical Officer at Vapotherm, shared her enthusiasm: "About 7,000 clinicians initially registered for our educational programs, and we are thrilled that even more participated as the value became more well-known.
  • Vapotherm is committed to partnering with clinicans to provide the highest level of patient care.
  • Dr. Whittle and Joe Army were both present at the American Association for Respiratory Care Congress to celebrate this accomplishment and educate about the HVT 2.0 system.

Vapotherm To Report Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
VAPO, Telephone, Security (finance), NYSE, Regulation Fair Disclosure, Regulation, Cryptocurrency, Vapotherm

EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.

Key Points: 
  • EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 12 months following completion of the call.

Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas

Retrieved on: 
Wednesday, October 4, 2023
Medical Supplies, Health, Medical Devices, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, COPD, Oxygen, Asthma, Engineering, Turbulence, VAPO, Ventilation, Chronic obstructive pulmonary disease, NYSE, Journal, Patient, Periodic breathing, Conference, CO2, Medical imaging, Vapotherm

Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.

Key Points: 
  • Computational fluid dynamics uses advanced computer algorithms to understand gas flow characteristics in changing and complex systems.
  • Vapotherm’s unique small bore design generates higher gas velocity distinguishing it from other forms of high flow cannulas.
  • The modeling confirmed that the higher velocity generated by the Vapotherm design results in improved CO2 flush compared to other cannulas.
  • ( https://dl.astfe.org/conferences/tfec2023,1ee0374044f80bd3,2fec083b2a0b5... )
    “This reaffirms that not all high flow devices are the same and shows the value of high velocity therapy for clearance of CO2 and flush of the upper airway,” said Brian Lawrence, Chief Technology Officer at Vapotherm.

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

Retrieved on: 
Monday, September 25, 2023
Medical Devices, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Asthma, University Hospitals Cleveland Medical Center, VAPO, Emergency department, CDC, Patient, Child, Asthma and Allergy Foundation of America, NHS, Periodic breathing, NYSE, Pharmaceutical industry, Vapotherm, DRS

The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.

Key Points: 
  • The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England under the direction of Drs.
  • Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy.
  • Eighty-six percent (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation.
  • Almost 5 million children in the USA, and 1 million children in the UK have asthma, according to the CDC and NHS.

Vapotherm Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Managed Care, Health, Medical Devices, Failure, Regulation Fair Disclosure, Table, Telephone, Vapotherm, GAAP, Cyprus Securities and Exchange Commission, Public expenditure, EBITDA, Depreciation, CUSIP, Security (finance), NYSE, Regulation, HVT, Bookkeeping, Eastern Time Zone, Adjustment

In the second quarter of 2023, gross margin increased by 780 basis points over gross margin of 35.0% in the first quarter of 2023.

Key Points: 
  • In the second quarter of 2023, gross margin increased by 780 basis points over gross margin of 35.0% in the first quarter of 2023.
  • Net loss for the second quarter of 2023 was $14.8 million, or $0.29 per share, compared to $42.7 million, or $1.61 per share, in the second quarter of 2022.
  • Net loss per share was based on 50,625,778 and 26,574,027 weighted average shares outstanding for the second quarter of 2023 and 2022, respectively.
  • Adjusted EBITDA was negative $6.4 million for the second quarter of 2023 as compared to negative $20.2 million for the second quarter of 2022.

Vapotherm To Report Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, July 25, 2023
Health, Medical Supplies, Other Health, Medical Devices, Telephone, Security (finance), VAPO, Regulation Fair Disclosure, NYSE, Regulation, Cryptocurrency, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 12 months following completion of the call.

Vapotherm Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Medical Devices, Other Health, Health, Medical Supplies, Loss, Failure, Regulation Fair Disclosure, Table, Telephone, Vapotherm, GAAP, Public expenditure, EBITDA, Depreciation, Security (finance), Regulation, HVT, Cryptocurrency, Bookkeeping, Adjustment

In the first quarter of 2023, gross margin increased by 750 basis points over gross margin of 27.5% in the fourth quarter of 2022.

Key Points: 
  • In the first quarter of 2023, gross margin increased by 750 basis points over gross margin of 27.5% in the fourth quarter of 2022.
  • Net loss for the first quarter of 2023 was $18.1 million, or $0.45 per share, compared to $22.9 million, or $0.87 per share, in the first quarter of 2022.
  • Net loss per share was based on 40,608,605 and 26,321,087 weighted average shares outstanding for the first quarter of 2023 and 2022, respectively.
  • Adjusted EBITDA was negative $9.2 million for the first quarter of 2023 as compared to negative $15.3 million for the first quarter of 2022.

Vapotherm To Report First Quarter 2023 Financial Results

Retrieved on: 
Thursday, April 27, 2023
Health, Medical Supplies, Other Health, Medical Devices, Telephone, Security (finance), VAPO, Regulation Fair Disclosure, NYSE, Regulation, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 12 months following completion of the call.

Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

Retrieved on: 
Friday, March 17, 2023
Health Technology, Health, Medical Supplies, Medical Devices, Calendar, VAPO, Cyprus Securities and Exchange Commission, Notice, Patient, Security (finance), Periodic breathing, NYSE, Vapotherm

As set forth in the Notice, as of March 14, 2023, the 30-trading day average closing share price of the Company’s common stock was $0.94 per share.

Key Points: 
  • As set forth in the Notice, as of March 14, 2023, the 30-trading day average closing share price of the Company’s common stock was $0.94 per share.
  • Pursuant to Section 802.01C, the Company has a period of six months following receipt of the Notice to regain compliance with the minimum share price requirement.
  • The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to trade on the NYSE during the applicable cure period, subject to all other listing requirements of the NYSE.
  • The “.BC” indicator will be removed at such time as the Company regains compliance with all continued listing standards.